<DOC>
	<DOCNO>NCT02776813</DOCNO>
	<brief_summary>This phase 1 , multi-center , single-arm , open-label study evaluate safety efficacy autologous T-cell product express ACTR combination rituximab subject refractory relapse CD20+ B-cell lymphoma .</brief_summary>
	<brief_title>Study ACTR087 Subjects With Relapsed Refractory B-cell Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Signed write informed consent obtain prior study procedure Histologicallyconfirmed relapse refractory CD20+ Bcell lymphoma one follow type , document disease progression recurrence follow immediate prior therapy : DLBCL , regardless cell origin underlie molecular genetics MCL PMBCL Gr3bFL THFL Biopsyconfirmed CD20+ expression underlie malignancy immunohistochemical staining flow cytometry recent dose antiCD20 monoclonal antibody ( mAb ) study enrollment At least 1 measurable lesion imaging . Lesions previously irradiate consider measurable progression document follow completion radiation therapy Must receive adequate prior therapy underlie CD20+ Bcell lymphoma , define antiCD20 mAb combination anthracyclinecontaining chemotherapy regimen ( i.e . chemoimmunotherapy ) least one following : biopsyproven refractory disease frontline chemoimmunotherapy relapse within 1 year frontline chemoimmunotherapy ineligible autologous hematopoietic stem cell transplant ( autoHSCT ) For subject DLBCL , PMBCL , Gr3bFL : relapsed refractory disease follow least 2 prior regimen follow autoHSCT For subject THFL : relapsed refractory disease follow least 2 prior regimen follow autoHSCT . At least 1 prior regimen antiCD20 mAb combination chemotherapy require follow documented transformation For subject MCL ( confirm cyclin D1 expression evidence ( 11 ; 14 ) cytogenetics , fluorescent situ hybridization ( FISH ) PCR ) : relapse refractory disease least 1 prior regimen chemoimmunotherapy ( prior autoHSCT allowable ) Karnofsky performance scale ≥ 60 % Life expectancy least 6 month ANC &gt; 1000/µL Platelet count &gt; 50,000/µL For woman childbearing potential ( define physiologically capable become pregnant ) , agreement use highly effective contraception least 1 year follow ACTR087 infusion . For men partner childbearing potential , agreement use effective barrier contraception least 1 year follow ACTR087 infusion Known active central nervous system ( CNS ) involvement malignancy . Subjects prior CNS involvement lymphoma must complete effective treatment CNS disease least 3 month prior enrollment evidence disease clinically least stable finding relevant CNS image Prior treatment follow : alemtuzumab within 6 month enrollment fludarabine , cladribine , clofarabine within 3 month enrollment external beam radiation within 2 week enrollment mAb ( include rituximab ) within 2 week enrollment lymphotoxic chemotherapy ( include steroid except ) within 2 week enrollment experimental agent within 3 halflives prior enrollment , unless progression document therapy Serum creatinine ≥ 1.5 X ageadjusted upper limit normal ( ULN ) Pulse oximetry &lt; 92 % room air Direct bilirubin ≥ 3.0 mg/dL ( 50 mmol/L ) Alanine transaminase ( ALT ) ≥ 3 time ULN , unless determine directly due lymphoma . Aspartate transaminase ( AST ) ≥ 3 time ULN , unless determine directly due lymphoma Class III IV heart failure define New York Heart Association ( NYHA ) , history cardiac angioplasty stenting , document myocardial infarction unstable angina within 6 month prior enrollment , cardiac ejection fraction &lt; 45 % , clinically significant cardiac disease Clinical history , prior diagnosis , overt evidence autoimmune disease , regardless severity Clinically significant active infection , judgment investigator Pregnancy ( negative serum pregnancy test obtain within 6 day prior enrollment subject childbearing potential ) Breastfeeding Primary immunodeficiency Seropositive Human Immunodeficiency Virus ( HIV ) 1 HIV 2 , positive hepatitis B surface antigen ( HBsAg ) hepatitis C antibody Will need need active treatment second malignancy within prior 3 year enrollment , FL , nonmelanoma skin cancer , localized prostate cancer treat curative intent , cervical carcinoma situ Is unable receive agent use study due history severe immediate hypersensitivity reaction ( e.g . hypersensitivity dimethyl sulfoxide ( DMSO ) ) History prior allogeneic HSCT History Richter 's transformation CLL Prior infusion genetically modify therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>CD20+</keyword>
	<keyword>B-cell</keyword>
	<keyword>ACTR087</keyword>
	<keyword>Relapsed</keyword>
	<keyword>Refractory</keyword>
</DOC>